impact factor
logo
 

Letters to the Editor

 

Acrocyanosis after neoadjuvant ipilimumab plus nivolumab: a case report


1, 2, 3, 4, 5, 6

 

  1. Department of Medical Oncology, and Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
  2. Department of Rheumatology and Clinical Immunology, and Department of Internal Medicine, Amsterdam UMC, the Netherlands.
  3. Department of Internal Medicine, Amsterdam UMC, the Netherlands, the Netherlands.
  4. Department of Rheumatology and Clinical Immunology, Amsterdam UMC, the Netherlands.
  5. Department of Rheumatology and Clinical Immunology, Amsterdam UMC, the Netherlands.
  6. Department of Medical Oncology, and Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands. c.blank@nki.nl

CER12841
2020 Vol.38, N°5
PI 1031, PF 1032
Letters to the Editor

Free to view
(click on article PDF icon to read the article)

PMID: 32301417 [PubMed]

Received: 07/10/2019
Accepted : 03/02/2020
In Press: 17/04/2020
Published: 02/10/2020

Rheumatology Article